NIH CRADA reasonable pricing clause removal under "serious discussion," NIH rep tells AIDS task force.
NIH CRADA REASONABLE PRICING CLAUSE COULD BE DROPPED, NIH officials say. Removal of the pricing clause from CRADA contracts is an option that is "under the most serious discussion at this point" among National Institutes of Health and Public Health Service representatives, NIH Acting Deputy Director for Science Policy & Technology Transfer Sandy Chamblee told the National Task Force on AIDS Drug Development in Bethesda, Md. on Jan. 19. Chamblee noted that at the December meetings of both the PHS Technology Transfer Board and NIH Advisory Board to the Director, participants agreed that the reasonable pricing clause in cooperative research and development agreements "should not be permitted to impede scientific collaboration" and "NIH itself is not a regulatory agency and should not take on a price-setting role."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth